Skip to main content
. 2023 Feb 28;9(1):e002676. doi: 10.1136/rmdopen-2022-002676

Figure 1.

Figure 1

Administration of burosumab during the interval between the end of the phase 3 study and the start of the open-label extension study. n=30; one participant who did not complete the phase 3 study through to week 96a was excluded from this exploratory analysis.